A new study is consistent with FDA’s black box requirements for antidepressants. Carlat Reports

A new study is consistent with FDA’s black box requirements for antidepressants.

The Carlat Psychiatry Report, Volume 6, Number 5, May 2008
https://www.thecarlatreport.com/newsletter-issue/tcprv6n5/

From The Carlat Psychiatry Report, May 2008, Neuropsychological Testing

Issue Links: Learning Objectives | Editorial Information

Dilip Jeste, MD

The FDA now requires antidepressant drug makers to carry black box warnings about an increased risk of suicidality in children and young adults.

You can't view details of this content, please login or buy subscription here

Dilip Jeste, MD

Estelle and Edgar Levi Chair in Aging, Professor of Psychiatry and Neurosciences Chief, Division of Geriatric Psychiatry, UC San Diego

Dr. Jeste has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jeste has disclosed that risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole are not FDA-approved for the treatment of agitation or psychosis in dementia. Please see product inserts for full lists of approved indications.